Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production.
Company (IPO / Went public)
269 East Grand Ave.
South San Francisco, 94080
California, United States
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)
|Inhibitors of lysine gingipain||Oct 05, 2015||Sep 12, 2017||Patent|
|Inhibitors of lysine gingipain||Aug 22, 2017||Application|
|Methods of use for therapeutics targeting the pathogen porphyromonas gingivalis||Apr 29, 2015||Application|